FDA Approvals - Episode 1

FDA Approval for Lutathera in Neuroendocrine Tumors

January 26, 2018

Now Viewing

EP. 1: FDA Approval for Lutathera in Neuroendocrine Tumors

EP. 2: FDA Approval of Second Dosing Schedule of Nivolumab

EP. 3: FDA Approval of Frontline Nivolumab/Ipilimumab Combo in RCC

EP. 4: FDA Approval of Durvalumab for Stage III Unresectable NSCLC

EP. 5: FDA Approval of Brentuximab Vedotin Plus AVD in Classical Hodgkin Lymphoma

EP. 6: FDA Approval of Frontline Osimertinib in Frontline EGFR-Mutant NSCLC

EP. 7: FDA Approval of Adjuvant Dabrafenib/Trametinib in BRAF+ Melanoma

EP. 8: FDA Approval of Frontline Daratumumab Plus VMP in Multiple Myeloma

Gina Columbus reports on the FDA approval to Lutathera (177Lutetium DOTA-octreotate) for the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).